Good
Mostly Aligned
Patient Risk:
Low
Summary
Most claims are general statements about generic availability and do not conflict with the supplied FDA label excerpts. However, the prompt’s label excerpts do not address generic availability, patent status, or country-specific generic approval; those claims are therefore unsupported relative to the provided label content.
Category Scores
Accurate Statements
Methylnaltrexone (Relistor) is used for opioid-induced constipation.
Label excerpt 1 INDICATIONS AND USAGE (1.1 and 1.2) indicates RELISTOR for treatment of opioid-induced constipation (OIC).
Unsupported Statements
The availability of a generic for Relistor depends on regulatory approval in the user’s country.
The supplied FDA label excerpts do not discuss generic availability, regulatory approval timing, or country-specific availability.
There is not enough detail provided to confirm a specific approved generic or biosimilar equivalent.
The supplied label excerpts do not provide any specific generic/biosimilar equivalence information; however, this claim is not supported or evaluated by the label content because no generic/biosimilar listings are included in the provided excerpts.
A drug may have an approved generic even if only the brand is visible.
The supplied label excerpts do not address whether generic approval exists when the brand is visible.
Actual market launch of a generic can lag behind patent status expiration.
The supplied label excerpts do not discuss patent status, generic market launch timing, or related regulatory/market dynamics.
Generic availability is country-specific.
The supplied label excerpts do not address how generic availability varies by country.
Contradictions
Low
AI Statement
Relistor is the brand name for methylnaltrexone.
Label Reference
RELISTOR (methylnaltrexone bromide) in the prompt-provided labeling context; no contradiction found in supplied excerpts.
Important Omissions
No omissions assessed because the user did not provide a label-related treatment claim requiring specific label elements (e.g., dosing, contraindications, warnings).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The only label-aligned clinical claim is the indication (OIC in adults). Other claims concern generic availability and do not provide dosing or safety instructions; thus they do not increase direct patient-risk based on the supplied label excerpts.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Several statements about generic/biosimilar availability, patent expiration, and country-specific launch/approval are not supported by the provided FDA label excerpts.
Suggested Improvement
Limit claims to information present in the supplied label excerpts (e.g., indications and administration/safety details) or remove generic-availability assertions unless supported by the label text provided.